Summary
MERIE PROJECT 1: SUMMARY/ABSTRACT Drugs are being developed to help people survive the effects of radiation from a large-scale event, such as detonation of an improvised nuclear device (IND). While several agents are already approved to treat hematopoietic acute radiation syndrome (H-ARS), which occurs at the lowest lethal radiation dose, there is still a need for mitigator drugs to treat injuries that occur at higher doses in other organ systems, such as the gut, lung, kidney and heart. Most mitigators are only tested with conventional dose rate x-rays, however, and not with the radiation ty
